Duloxetine in affective disorders

A naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups

Bernardo Dell'Osso, Giulia Camuri, Cristina Dobrea, Massimiliano Buoli, Marta Serati, A. Carlo Altamura

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is currently approved in many countries for the treatment of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The present naturalistic study was aimed to investigate tolerability of Duloxetine in a sample of patients with affective disorders and psychiatric/medical comorbidity, comparing tolerability in monotherapy versus polytherapy and across different age groups. Methods: The sample included 165 patients, affected by anxiety and/or mood disorders with or without comorbidity, who had been taken Duloxetine for at least 1 month. Sample variables were collected through a retrospective chart review. Results: Most common primary diagnoses were MDD (49.1 %), Bipolar Disorder (BD) (15.7 %) and GAD (5.5%). The 40 % of the sample had psychiatric comorbidity: in particular, anxiety disorders (15.8 %) (GAD 7.9%, Panic Disorder -PD- 7.3%) and personality disorders (9.1%) as the most frequent ones. With respect to medical comorbidities (68% of the sample), hypertension (12.1%) and diabetes (7.3%) were the most common ones. Mean duration of treatment and dosage of Duloxetine were, respectively, 11 months (± 9.1) and 70 mg/day (± 28.6). The 68 % of the sample received Duloxetine in association with other drugs. Minor side-effects, in particular drowsiness and gastrointestinal problems, were reported by 15 % of the sample. No difference in terms of tolerability across distinct groups, divided on the basis of mono- vs polytherapy as well as of different age, was found. Conclusion: Duloxetine, mostly administered in patients with affective disorders with psychiatric/ medical comorbidity and in association with other drugs, appeared to be well tolerated, showing limited rates of side effects of mild intensity. Further naturalistic studies are warranted to confirm present results.

Original languageEnglish
Pages (from-to)120-125
Number of pages6
JournalClinical Practice and Epidemiology in Mental Health
Volume8
DOIs
Publication statusPublished - 2012

Fingerprint

Mood Disorders
Psychiatry
Comorbidity
Anxiety Disorders
Age Groups
Major Depressive Disorder
Sleep Stages
Panic Disorder
Personality Disorders
Serotonin Uptake Inhibitors
Bipolar Disorder
Pharmaceutical Preparations
Duloxetine Hydrochloride
Hypertension
Therapeutics

Keywords

  • Affective disorders
  • Duloxetine
  • Medical comorbidity
  • Psychiatric comorbidity
  • Serotonin norepinephrine reuptake inhibitors
  • Tolerability

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Epidemiology

Cite this

@article{b5e7e140723741ada048d05429a26cc8,
title = "Duloxetine in affective disorders: A naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups",
abstract = "Objective: Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is currently approved in many countries for the treatment of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The present naturalistic study was aimed to investigate tolerability of Duloxetine in a sample of patients with affective disorders and psychiatric/medical comorbidity, comparing tolerability in monotherapy versus polytherapy and across different age groups. Methods: The sample included 165 patients, affected by anxiety and/or mood disorders with or without comorbidity, who had been taken Duloxetine for at least 1 month. Sample variables were collected through a retrospective chart review. Results: Most common primary diagnoses were MDD (49.1 {\%}), Bipolar Disorder (BD) (15.7 {\%}) and GAD (5.5{\%}). The 40 {\%} of the sample had psychiatric comorbidity: in particular, anxiety disorders (15.8 {\%}) (GAD 7.9{\%}, Panic Disorder -PD- 7.3{\%}) and personality disorders (9.1{\%}) as the most frequent ones. With respect to medical comorbidities (68{\%} of the sample), hypertension (12.1{\%}) and diabetes (7.3{\%}) were the most common ones. Mean duration of treatment and dosage of Duloxetine were, respectively, 11 months (± 9.1) and 70 mg/day (± 28.6). The 68 {\%} of the sample received Duloxetine in association with other drugs. Minor side-effects, in particular drowsiness and gastrointestinal problems, were reported by 15 {\%} of the sample. No difference in terms of tolerability across distinct groups, divided on the basis of mono- vs polytherapy as well as of different age, was found. Conclusion: Duloxetine, mostly administered in patients with affective disorders with psychiatric/ medical comorbidity and in association with other drugs, appeared to be well tolerated, showing limited rates of side effects of mild intensity. Further naturalistic studies are warranted to confirm present results.",
keywords = "Affective disorders, Duloxetine, Medical comorbidity, Psychiatric comorbidity, Serotonin norepinephrine reuptake inhibitors, Tolerability",
author = "Bernardo Dell'Osso and Giulia Camuri and Cristina Dobrea and Massimiliano Buoli and Marta Serati and Altamura, {A. Carlo}",
year = "2012",
doi = "10.2174/1745017901208010120",
language = "English",
volume = "8",
pages = "120--125",
journal = "Clinical Practice and Epidemiology in Mental Health",
issn = "1745-0179",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Duloxetine in affective disorders

T2 - A naturalistic study on psychiatric and medical comorbidity, use in association and tolerability across different age groups

AU - Dell'Osso, Bernardo

AU - Camuri, Giulia

AU - Dobrea, Cristina

AU - Buoli, Massimiliano

AU - Serati, Marta

AU - Altamura, A. Carlo

PY - 2012

Y1 - 2012

N2 - Objective: Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is currently approved in many countries for the treatment of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The present naturalistic study was aimed to investigate tolerability of Duloxetine in a sample of patients with affective disorders and psychiatric/medical comorbidity, comparing tolerability in monotherapy versus polytherapy and across different age groups. Methods: The sample included 165 patients, affected by anxiety and/or mood disorders with or without comorbidity, who had been taken Duloxetine for at least 1 month. Sample variables were collected through a retrospective chart review. Results: Most common primary diagnoses were MDD (49.1 %), Bipolar Disorder (BD) (15.7 %) and GAD (5.5%). The 40 % of the sample had psychiatric comorbidity: in particular, anxiety disorders (15.8 %) (GAD 7.9%, Panic Disorder -PD- 7.3%) and personality disorders (9.1%) as the most frequent ones. With respect to medical comorbidities (68% of the sample), hypertension (12.1%) and diabetes (7.3%) were the most common ones. Mean duration of treatment and dosage of Duloxetine were, respectively, 11 months (± 9.1) and 70 mg/day (± 28.6). The 68 % of the sample received Duloxetine in association with other drugs. Minor side-effects, in particular drowsiness and gastrointestinal problems, were reported by 15 % of the sample. No difference in terms of tolerability across distinct groups, divided on the basis of mono- vs polytherapy as well as of different age, was found. Conclusion: Duloxetine, mostly administered in patients with affective disorders with psychiatric/ medical comorbidity and in association with other drugs, appeared to be well tolerated, showing limited rates of side effects of mild intensity. Further naturalistic studies are warranted to confirm present results.

AB - Objective: Duloxetine, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is currently approved in many countries for the treatment of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). The present naturalistic study was aimed to investigate tolerability of Duloxetine in a sample of patients with affective disorders and psychiatric/medical comorbidity, comparing tolerability in monotherapy versus polytherapy and across different age groups. Methods: The sample included 165 patients, affected by anxiety and/or mood disorders with or without comorbidity, who had been taken Duloxetine for at least 1 month. Sample variables were collected through a retrospective chart review. Results: Most common primary diagnoses were MDD (49.1 %), Bipolar Disorder (BD) (15.7 %) and GAD (5.5%). The 40 % of the sample had psychiatric comorbidity: in particular, anxiety disorders (15.8 %) (GAD 7.9%, Panic Disorder -PD- 7.3%) and personality disorders (9.1%) as the most frequent ones. With respect to medical comorbidities (68% of the sample), hypertension (12.1%) and diabetes (7.3%) were the most common ones. Mean duration of treatment and dosage of Duloxetine were, respectively, 11 months (± 9.1) and 70 mg/day (± 28.6). The 68 % of the sample received Duloxetine in association with other drugs. Minor side-effects, in particular drowsiness and gastrointestinal problems, were reported by 15 % of the sample. No difference in terms of tolerability across distinct groups, divided on the basis of mono- vs polytherapy as well as of different age, was found. Conclusion: Duloxetine, mostly administered in patients with affective disorders with psychiatric/ medical comorbidity and in association with other drugs, appeared to be well tolerated, showing limited rates of side effects of mild intensity. Further naturalistic studies are warranted to confirm present results.

KW - Affective disorders

KW - Duloxetine

KW - Medical comorbidity

KW - Psychiatric comorbidity

KW - Serotonin norepinephrine reuptake inhibitors

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=84878126045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878126045&partnerID=8YFLogxK

U2 - 10.2174/1745017901208010120

DO - 10.2174/1745017901208010120

M3 - Article

VL - 8

SP - 120

EP - 125

JO - Clinical Practice and Epidemiology in Mental Health

JF - Clinical Practice and Epidemiology in Mental Health

SN - 1745-0179

ER -